




health

Department:
Health
REPUBLIC OF SOUTH AFRICA

INVITATION TO BID



HP13-2022ARV

Bid Description	Required At	Bid/Tender No	Closing Date and Time
<p>Supply and Delivery of Anti-Retroviral Medicines to the Department of Health for the period 1 July 2022 to 30 June 2025.</p> <p>Briefing Session: A non-compulsory online briefing session will be held via a Zoom Webinar on the 16th of July 2021 at 10H00. Bidders who wish to partake are required to register on Zoom Webinar not later than Thursday, close of business 15 July 2021, by using the following link.</p> <p>https://health-za.zoom.us/webinar/register/WN_J-y-Nw6rQxO2ZjBHCeRNyw</p> <p>Upon successful registration you will receive an email detailing your Meeting ID and password to access the Webinar.</p> <p>It is strongly recommended that all prospective bidders submit all enquiries, including possible problems being experienced with the registration process to tenders@health.gov.za. Prospective bidders must submit all enquiries on time to allow the response to reach the bidders before the tender closes.</p> <p>Bids obtainable from: The Department of Health website, www.health.gov.za & the temporary e-tender portal site on the National Treasury website.</p> <p>This will be published on the website on 9 July 2021. Bidders must click on the "TENDERS" tab and then on the "PHARMACEUTICAL TENDERS" tab to download the bid document.</p> <p>Deliver Bids to: Dr AB Xuma Building (previously known as Exarro) Voortrekker Street, Thaba Tshwane, Pretoria, 0143.</p> <p>For any information regarding this bid, please mail all inquiries to tenders@health.gov.za</p> <p>Hours: 07h30 - 15h30.</p>	<p>Department of Health, Dr AB Xuma Building (previously known as Exarro) Voortrekker Street, Thaba Tshwane, Pretoria, 0143.</p> <p>Evaluation Criteria</p> <p>This bid will be evaluated in four (04) Phases as indicated hereunder:</p> <ul style="list-style-type: none"> Phase I: Compliance with mandatory and other bid requirements Phase II: Compliance with technical specifications. Test reports received from sample evaluation. Phase III: Bids evaluated in terms of the 90/10 preference system. Phase IV: Recommendation and award. 	HP13-2022ARV	23 August 2021, 11:00